目的观察腔内激光联合聚桂醇泡沫硬化剂治疗下肢静脉曲张的临床效果。 方法回顾性分析2009年2月至2013年7月期间接受腔内激光联合聚桂醇泡沫硬化剂治疗的40例下肢静脉曲张患者（联合组）和单纯接受腔内激光治疗的40例下肢静脉曲张患者（对照组）的临床资料，比较2种治疗方法的效果。 结果联合组和对照组患者的手术时间〔（43.95±6.77）min比（45.20±6.77）min〕和术中出血量〔（16.07±4.30）mL比（16.65±4.50）mL〕比较差异均无统计学意义（P＞0.05），但联合组的手术费用低于对照组〔（7 056.83±940.45）元比（7 473.81±1 476.09）元〕，P=0.044。术后对照组的并发症发生率为20.0%（8/40），高于联合组的5.0%（1/40），差异有统计学意义（P=0.029）。术后所有患者获访4～24个月、（15.5±6.7）个月。随访期间，80例患者的下肢曲张畸形静脉均消失，对照组小范围复发3例（7.5%），联合组小范围复发2例（5.0%），2组复发率的差异无统计学意义（P=1.000）。 结论对下肢静脉曲张，腔内激光联合泡沫硬化剂治疗是一种安全和有效的新微创手术方法，具有并发症发生率低的优点，值得临床推广。
To standardize the treatment of secondary hyperparathyroidism and effectively meet the needs of practical clinical work, we gathered experts and nursing experts from Departments of Thyroid Surgery, Nephrology, Endocrinology and Metabolism, Nuclear Medicine, Ultrasound, Anesthesiology, Cardiology, and other departments at West China Hospital of Sichuan University to solicit opinions. This consensus was finally established based on published guidelines and the best evidence in Chinese and English combined with clinical practice. This consensus is intended to summarize and conclude, to the greatest extent possible, the practical issues encountered in diagnosing and treating secondary hyperparathyroidism in perioperative settings and to provide recommendations for clinical practice.